CliffBio
biologic

Enhertu

fam-trastuzumab deruxtecan-nxki

Loss of exclusivity—loss of exclusivity
CompanyDaiichi Sankyo →See this company's full patent-cliff portfolio

Drug detail

Brand nameEnhertu
Active ingredientfam-trastuzumab deruxtecan-nxki
Strength100MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Daiichi Sankyo

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.